Back to Type 2 Diabetes
This trial is complete. It is no longer accepting participants. Results may be available on ClinicalTrials.gov.

NCT01200394

NCT01200394
Completed Phase 2 🇦🇺 Australian site

Who may be able to join

Who might be able to join this trial:

  • You are 18 years old or older, and if you are female, you must not be able to become pregnant.
  • You have been diagnosed with type 2 diabetes and have moderate-to-severe chronic kidney disease, based on a specific kidney function measurement (eGFR) between 25 and 59 mL/min/1.73m².
  • Your urine tests have shown high levels of a protein called albumin leaking into your urine for more than 3 months (at a level of 300 mg/g or above).

Who may not be able to join:

  • Your kidney disease is caused by type 1 diabetes, or your kidney disease is not related to diabetes at all.
  • Your diabetes is not well controlled, meaning a blood test called HbA1c (which measures your average blood sugar over the past few months) shows a result above 9%.
  • You are currently taking two types of blood pressure/kidney-protecting medicines together — specifically an ACE inhibitor and an ARB at the same time (confirm with trial site if you are unsure which medications you take).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Trial details

Status
Completed
Phase
Phase 2
Sponsor
Pfizer
Registry
clinicaltrials_gov
Start date
1 December 2010
Est. completion
1 July 2013

Where this trial is recruiting

🇦🇺 Australia 🇨🇦 Canada 🇩🇰 Denmark Hong Kong 🇮🇳 India 🇲🇾 Malaysia 🇲🇽 Mexico 🇵🇱 Poland 🇷🇸 Serbia 🇸🇰 Slovakia 🇿🇦 South Africa 🇰🇷 South Korea 🇸🇪 Sweden 🇬🇧 United Kingdom 🇺🇸 United States

5 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Change From Baseline in Urinary Albumin Creatinine Ratio (UACR) at Week 12

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

View original record on ClinicalTrials.gov